Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. TMEM132A: a novel susceptibility gene for lung adenocarcinoma combined with venous thromboembolism identified through comprehensive bioinformatic analysis.Frontiers in oncology · 2025
   Article
2. The early and long-term occurrence of symptomatic venous thromboembolism after lung cancer surgery without extended thromboprophylaxis-a single center experience with 435 patients.Journal of thoracic disease · 2024
   Article
3. A New Risk Prediction Model for Venous Thromboembolism and Death in Ambulatory Lung Cancer Patients.Cancers · 2023
   Article
4. Pro-Tumorigenic and Thrombotic Activities of Platelets in Lung Cancer.International journal of molecular sciences · 2023
   Review
5. Association between length of stay and postoperative survival in patients with lung cancer: a propensity score matching analysis based on National Cancer Database.Journal of thoracic disease · 2023
   Article
6. Correlation between clinicopathological characteristics of lung adenocarcinoma and the risk of venous thromboembolism.Thoracic cancer · 2022
   Observational
7. Is There an Interplay between Immune Checkpoint Inhibitors, Thromboprophylactic Treatments and Thromboembolic Events? Mechanisms and Impact in Non-Small Cell Lung Cancer Patients.Cancers · 2019
   Article
8. Risk factors and prognosis value of venous thromboembolism in patients with advanced non-small cell lung cancer: a case-control study.Journal of thoracic disease · 2017
   Article

Corrections and comments

• Erratum for
  Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data.2016

Authors and funding

6 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.